checkAd

     141  0 Kommentare Cidara Therapeutics Announces Divestiture of Rezafungin to Mundipharma* to Focus on Advancing the Clinical Development of Cloudbreak DFC Pipeline - Seite 3

    INVESTOR CONTACT:
    Brian Ritchie
    LifeSci Advisors
    (212) 915-2578
    britchie@lifesciadvisors.com

    MEDIA CONTACT:
    Michael Fitzhugh
    LifeSci Communications
    mfitzhugh@lifescicomms.com

    Lesen Sie auch

     


    Diskutieren Sie über die enthaltenen Werte


    globenewswire
    0 Follower
    Autor folgen
    RSS-Feed abonnieren

    Weitere Artikel des Autors

    Seite 3 von 3

    Verfasst von globenewswire
    1 im Artikel enthaltener WertIm Artikel enthaltene Werte
    Cidara Therapeutics Announces Divestiture of Rezafungin to Mundipharma* to Focus on Advancing the Clinical Development of Cloudbreak DFC Pipeline - Seite 3 Transaction provides company with an estimated approximately $128 million in cost savings, including approximately $67 million in clinical development and CMC costs over the next three years and an additional approximately $61 million in forecasted …

    Auch bei Lesern beliebt

    Schreibe Deinen Kommentar

    Disclaimer